Aclidinium bromide/formoterol rebate agreements 2026-06

Summary

The tender concerns an open-house accession procedure for medicines containing the active substance combination aclidinium bromide/formoterol. It is a rebate-agreement type arrangement under which suitable pharmaceutical companies may join on uniform terms; no individual negotiations are held and no exclusivity is granted. For TK, the contract runs for a maximum of 24 months from 01/09/2026 and ends no later than 31/08/2028. Joining is possible at any time during the contract term.